GE Healthcare, originating from the healthcare business segment of General Electric Company in the United States, underwent a spin-off and became independently listed on NASDAQ in January 2023. Its business spans four major areas: medical imaging, ultrasound, patient care solutions, and diagnostic medicine. The company's predecessor can be traced back to its first office established in China in 1986, followed by the establishment of the GE Hangwei joint venture factory in 1991. In China, it has production bases in Beijing, Shanghai, and Wuxi. In 2024, the Tianjin magnetic resonance base was listed as the headquarters for the Eastern Hemisphere, and the Wuxi headquarters for ultrasound in Greater China was established. The Beijing imaging equipment manufacturing base was selected as a "Lighthouse Factory". In 2025, it signed a contract with Alibaba's DAMO Academy to introduce "One Scan, Multiple Diagnoses" AI imaging technology, and collaborated with Shanghai Ruijin Hospital on the clinical validation of the new generation Omni128 long-axis PET/CT. In December of the same year, technetium [99ᵐTc] tetramethylenetetramine phosphate injection became the first diagnostic nuclear medicine to be included in the national medical insurance directory. The Tianjin magnetic resonance Eastern Hemisphere headquarters innovation center was put into operation